Table 1.
Cohort characteristics
| ID cohort | Non-ID cohort | |
| Total number (%) | 9039 (21) | 34 242 (79) |
| Male, n (%) | 5279 (58) | 18 825 (55) |
| Average age, years (SD) | 42 (16) | 44 (16) |
| Townsend score, n (%) | ||
| 1 | 1403 (16) | 4860 (14) |
| 2 | 1752 (19) | 5119 (15) |
| 3 | 1948 (22) | 6481 (19) |
| 4 | 1942 (22) | 8189 (24) |
| 5 | 1563 (17) | 7911 (23) |
| Missing | 417 (5) | 1619 (5) |
| History of antipsychotic use at cohort entry, n (%) | 6684 (74) | 16 227 (47) |
| History of movement disorder at cohort entry, n (%) | 2192 (24) | 4946 (14) |
| History of movement disorder without antipsychotic use at cohort entry, n (%) | 136/2355 (6) | 1038/18 015 (6) |
| History of movement disorder and antipsychotic use at cohort entry, n (%) | 2056/6684 (31) | 3908/16 227 (24) |
| Total person-years between first and last antipsychotic prescription | 44 696 | 104 014 |
| Median years between first and last prescription (IQR) | 3.5 (1.2 to 7.9) | 1.3 (0.19 to 4.4) |
| Median years on treatment between first and last prescription (IQR) | 2.6 (0.76 to 6.3) | 0.67 (0.15 to 2.5) |
| Average daily dose, CLZE (SD) | 135 (156) | 139 (146) |
CLZE, chlorpromazine equivalents; ID, intellectual disability.